Conservative Balance SheetVery low leverage and a large equity base materially reduce near-term refinancing risk and give management flexibility to pursue clinical programs and partner negotiations over the next several quarters, improving solvency resilience despite operating losses.

Proprietary Immunotherapy PipelineA focused, proprietary candidate platform (ALZ-101) targeting amyloid‑beta aggregates addresses a large unmet market in Alzheimer’s. Clinical-stage, differentiated science can create durable value via partnerships, licensing, or milestone-driven financing if clinical progress continues.

Cash Efficiency Vs Accounting LossesFree cash flow being proportionally less negative than accounting losses suggests parts of R&D spend include non‑cash items or timing differences, which can moderate immediate cash needs and support negotiation of staged funding or milestone deals in the medium term.

Bears Say

High And Persistent Cash BurnLarge negative operating and free cash flows are structural for an early biotech but imply ongoing dependence on external financing. Persistent burn increases dilution risk, constrains strategic optionality, and pressures timelines for partnerships or capital raises over coming quarters.

Pre-revenue And Volatile RevenuesExtremely small, volatile revenue underscores a pre‑commercial profile with no sales cushion. This structural absence of recurring revenue elevates dependency on milestone payments, grants, or equity raises, increasing execution risk until clinical validation or partnerships materialize.

Negative Return On EquitySustained negative ROE indicates R&D investment has not yet generated shareholder value. Over time this can erode investor confidence, raise the cost of capital, and make future fundraising more dilutive, constraining long‑term strategic flexibility if outcomes lag.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.68 and its highest was kr3.82 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr118.68M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Feb 26, 2026 which is in 6 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on Nov 13, 2025. The company reported -kr0.067 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.067.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 166,917,740 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.067 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 28.525%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.